I have been doing research on BOTH AVXL & SAVA. But this cogent article sold me;
https://seekingalpha.com/article/4443027-casava-sciences-simufilam-first-alzheimers-drug-to-work-at-9-months

...as I believe SAVA is further along.

Moreover, with very little market penetration, & in ONLY the U.S., the price is EXTREMELY UNDERVALUED. So with the hit piece FDA petition COORDINATED with a bogus attempt at a class action I bought 2,500 shares of SAVA pre-market low $80 & change & then some at market open.

Very happy!

I'd like to see more progress here before I do likewise... But I also think SAVA has the larger market overall, plus the blood test will be worth the CURRENT Market Cap if these final hurdles go as expected.

The NOVEL APPROACH to solving the problem, versus every other lab is what sold me. GLA

What I believe to be a POORLY RESEARCHED filing (they weren't even AWARE that testing & results were REPORTED by an independent & respected THIRD PARTY industry participant). https://www.regulations.gov/docket/FDA-2021-P-0930/document